Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with early or advanced idiopathic Parkinson's Disease~* Patients with advanced idiopathic Parkinson's Disease: intake of Levodopa on a stable dose of at least 200 mg/day~* Unsatisfactory control of Parkinson's Disease motor symptoms under current treatment~* Patients experiencing Apathy associated with Parkinson's Disease~* Hoehn and Yahr stage score of I to IV~* Mini-Mental State Examination score ≥ 25~* If an antidepressant drug is taken, the dose must be stable~Exclusion Criteria:~* Therapy with a Dopamine agonist~* Discontinuation from pervious therapy with a dopamine agonist after an adequate length of treatment, at adequate dose, due to lack of efficacy~* Any medical or psychiatric condition that jeopardizes / compromises patient's ability for participation~* Patient has received Neuroleptics, Dopamine releasing substances, Dopamine modulating substances, Alpha-Methyldopa, Metoclopramide, MAO-A inhibitors, Budipine, or Tolcapone~* Electroconvulsive therapy~* Patient has a~  * current/anticipated psychotherapy or behavior therapy~ * history of deep brain stimulation~ * history of suicide attempt or has suicidal ideation~ * impulse control disorder~ * severe Depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rotigotine, high dose (Type: EXPERIMENTAL): Rotigotine, transdermal patches, maximal 16 mg / 24 hours for patients with advanced Parkinson's Disease and 8 mg / 24 hours for those with early Parkinson's Disease
- Rotigotine, low dose (Type: EXPERIMENTAL): Rotigotine, transdermal patches, optimal dose, maximal 8 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours for those with early Parkinson's Disease
- Placebo (Type: PLACEBO_COMPARATOR): Placebo transdermal patches

Based on this trial design, predict the completion outcome and termination type (if applicable).